RxDoctor Payments Data

Thomas John, MD

Internal Medicine · New Hartford, NYNPI 1770577884

Payments from drug & device makers

$16,714in general payments, 2019–2025

Across 962 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Pfizer$2K
  • AstraZeneca$2K
  • Novo Nordisk$1K
  • GSK$1K
  • Lilly USA, LLC$1K
  • plus $8K from 43 others

What the payments were for

  • Food & beverage$16,61499%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,714 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$268,132
Medicare patients
550
Services billed
3,384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$73,470
OzempicSemaglutide50$50,531
JardianceEmpagliflozin41$47,588
XareltoRivaroxaban41$42,833
EntrestoSacubitril/Valsartan38$39,070
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$38,346
JanuviaSitagliptin Phosphate22$31,637
RybelsusSemaglutide20$23,872
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$20,259
FarxigaDapagliflozin Propanediol25$20,162
Repatha SureclickEvolocumab18$14,890
KerendiaFinerenone17$13,181
Spiriva RespimatTiotropium Bromide16$11,722
VascepaIcosapent Ethyl13$10,971
PaxlovidNirmatrelvir/Ritonavir13$10,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$1,713$84,35788 claims
Novo NordiskOzempic, Rybelsus$1,089$74,40370 claims
Boehringer IngelheimJardiance, Spiriva Respimat$621$59,31057 claims
Johnson & JohnsonXarelto$206$42,83341 claims
MerckJanuvia, Janumet Xr$368$41,27145 claims
AstraZenecaBreztri Aerosphere, Farxiga$1,626$40,42152 claims
NovartisEntresto$302$39,07038 claims
GSKTrelegy Ellipta$1,039$38,34635 claims
BayerKerendia$344$13,18117 claims
AbbVieSynthroid$2,686$2,63366 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New Hartford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →